Post written by Adi Hoess, CEO
Recently, Ray Jupp, CSO and I went to ASGCT’s 2026 annual meeting in Boston, which showcased a range of viral and non-viral delivery platforms. Excellent progress has been made with non-viral delivery and the presentations were packed. Improvements were presented around cell-specific targeting, liver de-targeting, reducing inflammation and immune responses and payload design. Still, most data remain pre-clinical, and the future clinical challenges are yet to be fully understood.
Among the non-viral approaches discussed, most were based on lipid nanoparticles (LNPs); however, a few new delivery options were also showcased, including ViaNautis’ targeted polyNaut nanovesicles (tPNVs). We had an intense time at our poster and drug developers were keen to learn more about our tPNVs. We came away with lots of positive feedback and interests for future conversations. The key points of discussion were:
- Unlike tLNPs that require active de-targeting from the liver, tPNVs are inert and through nanobody conjugation, can achieve precise cell-specific delivery.
- No inflammation or immunogenicity is observed, supporting repeat dosing.
- Broad cargo options are available, including DNA, mRNA, ASO and siRNA, with cargo sizes beyond 7kb.
- Route of administration can either be intravenous (IV) or subcutaneous (SC), whereby SC administration of tPNV showed similar results as with IV administration.
At ViaNautis, we are encouraged by the recent progress in our I&I and CNS programmes. tPNVs could offer a new solution to the challenges that other technologies face.
To learn more about ViaNautis’ tPNVs, check out our poster presented at ASGCT.